Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Kraunus

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Gene Therapy|March 19, 2004
B-cell-specific transgene expression using a self-inactivating retroviral vector with human CD19 promoter and viral post-transcriptional regulatory elementM Werner, J Kraunus, C Baum, et al.
Gene Therapy|September 17, 2004
Self-inactivating retroviral vectors with improved RNA processingJ Kraunus, D H S Schaumann, J Meyer, et al.
Immunity|December 9, 1997
Early lethality, functional NF-kappaB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient miceW C Yeh, A Shahinian, D Speiser, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Gene Therapy|March 19, 2004
B-cell-specific transgene expression using a self-inactivating retroviral vector with human CD19 promoter and viral post-transcriptional regulatory elementM Werner, J Kraunus, C Baum, et al.
Gene Therapy|September 17, 2004
Self-inactivating retroviral vectors with improved RNA processingJ Kraunus, D H S Schaumann, J Meyer, et al.
Immunity|December 9, 1997
Early lethality, functional NF-kappaB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient miceW C Yeh, A Shahinian, D Speiser, et al.
Pageof 1